For the fiscal year ended July 2026, the company implemented growth investments in the first half and shifted to profitability in the second half. Operating income increased 11.2% year-over-year, and net income attributable to owners of parent rose 439% year-over-year. Net sales decreased 3.1% year-over-year. Investments in a new factory and initiatives to strengthen the balance sheet alongside increased treasury stock progressed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2929","jir_company_name":"Pharma Foods International Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/2929-20260928-01.pdf","jir_short_summary":"For the fiscal year ended July 2026, the company implemented growth investments in the first half and shifted to profitability in the second half. Operating income increased 11.2% year-over-year, and net income attributable to owners of parent rose 439% year-over-year. Net sales decreased 3.1% year-over-year. Investments in a new factory and initiatives to strengthen the balance sheet alongside increased treasury stock progressed.","jir_summary":"### Overview of Performance\nFor the fiscal year ended July 2026, in line with the initial plan the company continued investments in the first half to drive growth and shifted to profit generation in the second half. Revenue improvement was strengthened in the fourth quarter, resulting in operating income increasing 11.2% year-over-year and net income improving significantly by 439% year-over-year. Net sales decreased 3.1% year-over-year, while segment-level investments and optimization progressed in both BtoC and BtoB. Growth investments related to the new factory construction and improvements in financial soundness are underway.\n\n### Impact on Shareholders and Financial Stability\nTangible fixed assets increased due to fixed asset additions and the new factory investment. Current assets slightly declined, but the year-end equity ratio improved to 37.5%. Through increased retained earnings and an improved equity ratio, funding for growth investments has been secured. Cash and cash equivalents remained stable at the fiscal year-end.","jir_financial_highlights":"Net Sales: 63,223 (Year-over-Year -3.1%)\nGross Profit: 50,693 (Year-over-Year -3.6%)\nOperating Income: 2,632 (Year-over-Year +11.2%)\nOrdinary Income: 2,440 (Year-over-Year -4.4%)\nNet Income Attributable to Owners of Parent: 1,988 (Year-over-Year +439%)\nEquity Ratio: 37.5 (Year-over-Year +2.1pt)\nInterest-Bearing Debt Balance: 17,171 (Year-over-Year +4,540)","jir_category":"","jir_hashtags":"#PharmaFoodsInternational, #FinancialResults, #GrowthInvestment","jir_key_figures":"Net Sales: 63,223 million yen (Year-over-Year -3.1%)\nOperating Income: 2,632 million yen (Year-over-Year +11.2%)\nNet Income Attributable to Owners of Parent: 1,988 million yen (Year-over-Year +439%)","jir_meta_title":"Pharma Foods International Co., Ltd. - Supplementary Materials for the Year Ended July 2026 | Growth Investments and Significant Profit Increase","jir_meta_description":"Summary of Pharma Foods International Co., Ltd.'s supplementary materials for the fiscal year ended July 2026. Growth investments were made in the first half and profitability improved in the second half. Operating income increased 11.2%, net income rose 439%, and the equity ratio improved to 37.5%. Detailed segment trends and financial condition are provided.","jir_og_title":"Pharma Foods International - Supplementary Financial Materials for Year Ended July 2026 | Growth Investments and Profit Shift","jir_og_description":"Supplementary financial materials for the fiscal year ended July 2026. Continued growth investments with revenue improvement in the fourth quarter. Operating income +11.2%, net income +439%.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57923,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-123495","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n